Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Boosted by American Century Companies Inc.

American Century Companies Inc. boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 301,087 shares of the company's stock after buying an additional 17,103 shares during the period. American Century Companies Inc.'s holdings in Takeda Pharmaceutical were worth $3,986,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in TAK. Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical during the fourth quarter worth about $26,000. Wilmington Savings Fund Society FSB bought a new position in Takeda Pharmaceutical in the 3rd quarter worth about $40,000. BNP Paribas Financial Markets increased its stake in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after purchasing an additional 2,596 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares during the last quarter. Finally, Cromwell Holdings LLC bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $61,000. 9.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of TAK traded down $0.48 during trading hours on Thursday, reaching $13.87. 2,876,249 shares of the company's stock traded hands, compared to its average volume of 1,854,553. The firm has a market capitalization of $44.12 billion, a price-to-earnings ratio of 34.66, a P/E/G ratio of 0.24 and a beta of 0.39. The business's fifty day simple moving average is $14.45 and its two-hundred day simple moving average is $13.91. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.